Attovia Therapeutics Inc., an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5 million in a US initial public offering.
Science Bloomberg Jul 29, 2026
Goldman-Backed Biotech Attovia Seeks $212.5 Million in US IPO
Attovia Therapeutics Inc., an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5 million in a US initial public offering.
